Cover Image

Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the COVID-19 Pandemic

ObjectiveThis study was designed to evaluate the efficacy of remote medication management of rivaroxaban by pharmacists for geriatric patients with nonvalvular atrial fibrillation during the COVID-19 pandemic.MethodsA single-site, prospective cohort study was conducted among patients with non-valvul...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaoye Li (Author), Chengchun Zuo (Author), Wenjing Lu (Author), Ye Zou (Author), Qing Xu (Author), Xiaoyu Li (Author), Qianzhou Lv (Author)
Format:	Book
Published:	Frontiers Media S.A., 2020-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation
by: Xiaoye Li, et al.
Published: (2021)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
by: Miller JD, et al.
Published: (2016)

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation
by: Huamin Ding, et al.
Published: (2024)

Evaluation of pharmacist-led telemedicine medication management for hypertension established patients during COVID-19 pandemic: A pilot study
by: Xiaoye Li, et al.
Published: (2022)

ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS
by: A. Y. Rychkov, et al.
Published: (2016)

EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN THE PREVENTION OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN EVERYDAY CLINICAL PRACTICE: FACTS ABOUT RIVAROXABAN
by: I. S. Yavelov
Published: (2016)

Perioperative Treatment with Rivaroxaban and Dabigatran on Changes of Coagulation and Platelet Activation Biomarkers following Left Atrial Appendage Closure
by: Yao Yao, et al.
Published: (2024)

Cost effectiveness of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia: A Single-Center retrospective cohort study
by: Yazed AlRuthia, et al.
Published: (2023)

Rivaroxaban in atrial fibrillation cardioversion: an update
by: Lavalle C, et al.
Published: (2019)

Predictors of Thrombus Dissolution in the Left Atrial Appendage in Patients with Persistent Nonvalvular Atrial Fibrillation
by: E. S. Mazur, et al.
Published: (2022)

A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation
by: Nan Zhao, et al.
Published: (2022)

The Impact of Dabigatran and Rivaroxaban on Variation of Platelet Activation Biomarkers and DRT Following Percutaneous Left Atrial Appendage Closure
by: Xiaoye Li, et al.
Published: (2021)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016)

Incidence of cerebral microembolization in patients with nonvalvular atrial fibrillation using transcranial Doppler
by: Hamouda A.K.H El-Bahnasy, et al.
Published: (2022)

A cross-sectional study of appropriateness evaluation of anticoagulation therapy for inpatients with nonvalvular atrial fibrillation
by: Xiao-Yuan Zheng, et al.
Published: (2023)

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol
by: Josep Comin Colet, et al.
Published: (2023)

Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease
by: I. S. Daabul, et al.
Published: (2016)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
by: Turpie AGG
Published: (2014)

Atrial fibrillation in elderly patients. Features of using rivaroxaban
by: A. D. Erlikh
Published: (2020)

Twice-daily rivaroxaban after percutaneous left atrial appendage closure for atrial fibrillation
by: Yang-Qi Pan, et al.
Published: (2024)

Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study
by: Li X, et al.
Published: (2021)

ATRIAL FIBRILLATION COMBINED WITH DIABETES MELLITUS. POSSIBILITIES OF USING RIVAROXABAN
by: Alexey D. Ehrlich
Published: (2018)

Antithrombotic therapy and clinical characteristics of patients hospitalized for nonvalvular atrial fibrillation in Galician internal medicine clinics
by: Jose Manuel Cerqueiro-Gonzelez, et al.
Published: (2019)

Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark
by: Poulsen PB, et al.
Published: (2017)

Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience
by: Shaban Mohammed, et al.
Published: (2017)

The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports
by: Tomić Milan
Published: (2020)

Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy
by: E. S. Mazur, et al.
Published: (2021)

Estimation of left atrial appendage wall motion velocity in patients with persistent nonvalvular atrial fibrillation and its effect on thrombotic risk
by: Waleed Yousof, et al.
Published: (2021)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023)

The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation
by: I. A. Zolotovskaya, et al.
Published: (2021)

Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients
by: Robyn Konicki, et al.
Published: (2020)

DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER
by: I. S. Yavelov
Published: (2016)

Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies
by: Bo Cao, et al.
Published: (2021)

Type 2 diabetes mellitus and nonvalvular atrial fibrillation in Mexico: national registries raise a red flag
by: Manlio F. Márquez-Murillo, et al.
Published: (2023)

Topical issues of dabigatran use in combination antithrombotic therapy in patients with acute coronary syndrome and nonvalvular atrial fibrillation
by: N. A. Novikova, et al.
Published: (2020)

THROMBUS OF LEFT ATRIUM AND/OR ITS APPENDAGE IN CASE OF NONVALVULAR ATRIAL FIBRILLATION: FREQUENCY OF DETECTION AND CLINICAL RISK FACTORS
by: I. A. Zaigrayev, et al.
Published: (2020)

Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry
by: Michihiro Suwa, et al.
Published: (2024)

Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban
by: Francisco Marin, et al.
Published: (2023)